Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><strong><em>Highlights include data from non-clinical and microbiology programs and real-world patient use</em></strong><br /></p> <p align="justify">BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...